These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27539143)

  • 21. Are third-generation active-targeting nanoformulations definitely the best? In vitro and in vivo comparisons of pixantrone-loaded liposomes modified with different sialic acid derivatives.
    Song Y; She Z; Huang Z; Wang S; Liu X; Zhang Q; Sun J; Di D; Deng Y
    Drug Deliv Transl Res; 2022 Mar; 12(3):647-661. PubMed ID: 33928513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphatidylserine and/or Sialic Acid Modified Liposomes Increase Uptake by Tumor-associated Macrophages and Enhance the Anti-tumor Effect.
    Xu Z; Li J; Yan N; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2024 Jun; 25(5):125. PubMed ID: 38834759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
    Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
    J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sialic Acid Conjugate-Modified Liposomal Dexamethasone Palmitate Targeting Neutrophils for Rheumatoid Arthritis Therapy: Influence of Particle Size.
    Wang S; Yang S; Lai X; Song Y; Hu L; Li C; Shi T; Liu X; Deng Y; Chen G
    AAPS PharmSciTech; 2021 Jan; 22(1):16. PubMed ID: 33389218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sialic acid-conjugate modified liposomes targeting neutrophils for improved tumour therapy.
    Li C; Qiu Q; Liu M; Liu X; Hu L; Luo X; Lai C; Zhao D; Zhang H; Gao X; Deng Y; Song Y
    Biomater Sci; 2020 Apr; 8(8):2189-2201. PubMed ID: 32096498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer.
    Lu S; Xu L; Kang ET; Mahendran R; Chiong E; Neoh KG
    Eur J Pharm Sci; 2016 Mar; 84():103-15. PubMed ID: 26780592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation and comparative in vitro evaluation of various dexamethasone-loaded pH-sensitive polymeric nanoparticles intended for dermal applications.
    Sahle FF; Gerecke C; Kleuser B; Bodmeier R
    Int J Pharm; 2017 Jan; 516(1-2):21-31. PubMed ID: 27845215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
    Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
    Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and characterization of isoniazid-loaded crude soybean lecithin liposomes.
    Nkanga CI; Krause RW; Noundou XS; Walker RB
    Int J Pharm; 2017 Jun; 526(1-2):466-473. PubMed ID: 28461265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exhausting tumor associated macrophages with sialic acid-polyethyleneimine-cholesterol modified liposomal doxorubicin for enhancing sarcoma chemotherapy.
    Zheng H; Li J; Wang M; Luo X; Qiu Q; Hu L; Li C; Song Y; Deng Y
    Int J Pharm; 2019 Mar; 558():187-200. PubMed ID: 30654062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the antitumor effects of vitamin K
    Shi J; Zhou S; Kang L; Ling H; Chen J; Duan L; Song Y; Deng Y
    Drug Deliv Transl Res; 2018 Feb; 8(1):1-11. PubMed ID: 28849577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization design of sialic acid derivatives enhances the performance of liposomes for modulating immunosuppressive tumor microenvironments.
    Sui D; Liang K; Gui Y; Du Z; Xin D; Yu G; Zhai W; Liu X; Song Y; Deng Y
    Life Sci; 2022 Dec; 310():121081. PubMed ID: 36273630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
    Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
    Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chitosan-modified lipid nanodrug delivery system for the targeted and responsive treatment of ulcerative colitis.
    Chen SQ; Song YQ; Wang C; Tao S; Yu FY; Lou HY; Hu FQ; Yuan H
    Carbohydr Polym; 2020 Feb; 230():115613. PubMed ID: 31887935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
    Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
    J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential administration of sialic acid-modified liposomes as carriers for epirubicin and zoledronate elicit stronger antitumor effects with reduced toxicity.
    Sui D; Tang X; Ding J; Wang Y; Qin Y; Zhang N; Liu X; Deng Y; Song Y
    Int J Pharm; 2021 Jun; 602():120552. PubMed ID: 33798685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.